A novel new treatment may soon be available from Ixodes, a Swiss pharmaceutical company focused on developing and commercializing therapeutic products for the prevention of Lyme Disease.
Ixodes announced in early March that the company has reached agreement with the US Food and Drug Administration (FDA) on the phase III protocol according to the Special Protocol Assessment (SPA) for its lead product candidate, Ixogel®, for the prevention of Lyme Disease after a tick bite. FDA had already designated Ixogel® as a Qualified Infectious Disease Product (QIDP).
“Ixodes AG is delighted that the FDA has agreed on our phase III protocol according to Special Protocol Assessment (SPA) and given Ixogel® a QIDP designation, further affirming the importance of addressing the serious medical need related to Lyme Disease due to tick bites,” says Gustave Huber, Ixodes Chief Executive Officer. “The QIDP designation and the SPA agreement with the FDA on the Phase III protocol will strongly support our goal to bring Ixogel® to the U.S. and European markets as fast as possible.”
In order to achieve QIDP designation, a drug product must be intended to treat serious or life-threatening infections, particularly infections caused by “qualified pathogens” as determined by the FDA. These pathogens include Borrelia burgdorferi, the pathogen causal for Lyme Disease.
Ixogel’s accelerated approval designation provides Ixodes AG with the opportunity to meet with the FDA on a more frequent basis during the review process and provides eligibility for priority review of the marketing application.